IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors

COPENHAGEN, Denmark, June 11, 2018 -- (Healthcare Sales & Marketing Network) -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win technology, today announced th... Biopharmaceuticals, Oncology, Personnel IO Biotech, T-Win, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news